Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats

[Display omitted] Erythropoietin (EPO) has been shown to protect the heart against acute myocardial infarction in pre-clinical studies, however, EPO failed to reduce infarct size in clinical trials and showed significant safety problems. Here, we investigated cardioprotective effects of two selectiv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacological research 2016-11, Vol.113 (Pt A), p.62-70
Hauptverfasser:	Kiss, Krisztina, Csonka, Csaba, Pálóczi, János, Pipis, Judit, Görbe, Anikó, Kocsis, Gabriella F., Murlasits, Zsolt, Sárközy, Márta, Szűcs, Gergő, Holmes, Christopher P., Pan, Yijun, Bhandari, Ashok, Csont, Tamás, Shamloo, Mehrdad, Woodburn, Kathryn W., Ferdinandy, Péter, Bencsik, Péter
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myocardial infarction Animals B-type natriuretic peptide Cardioprotection Cardiotonic Agents - pharmacology Darbepoetin Erythropoietin Erythropoietin - metabolism Ligands Male Myocardial Infarction - drug therapy Myocardial Infarction - metabolism Myocardial Reperfusion Injury - drug therapy Myocardial Reperfusion Injury - metabolism Myocardium - metabolism Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Natriuretic Peptide, Brain - pharmacology Non-erythropoietic EPO receptor ligand Pilot Projects Rats Rats, Wistar
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!